Memórias do Instituto Oswaldo Cruz
BACKGROUND Chagas disease (CD) is a tropical neglected disease caused by the protozoan Trypanosoma cruzi. The therapy based on two nitro derivatives is outdated, exhibits toxicity and has limited efficacy. OBJECTIVES This report reviews the successful interaction of multidisciplinary teams of medicinal chemistry, pharmacology and parasitology research groups belonging to FIOCHAGAS program, with the goal of finding new drug candidates for CD. METHODS Based on drug repositioning and combination strategies, drug candidates acting on different mechanisms of action, such as (i) tyrosine kinase inhibitors (imatinib - IMB) and (ii) ergosterol biosynthesis inhibitors (atorvastatin - AVA), were investigated in non-clinical studies to detect anti-T. cruzi activity/selectivity as well as ADMET and safety profile. These studies (in silico and in vitro,) were guided by standardised protocols, constructed from a flowchart that identifies promising candidates for the treatment of CD. FINDINGS Despite the known limited efficacy of several statins in monotherapy approach, AVA-aminoquinoline hybrids emerged as promising antiparasitic agents, developed through a synthetic pharmaceutical innovation platform that combines molecular hybridisation and phenotypic approaches. IMB and derivatives represent another successful example of drug repositioning, revealing antitrypanosomal activity through the modulation of kinase-related pathways relevant to T. cruzi infection. One of them, LS2/89 reached EC50 of 0.19 μM, being about 22-fold more potent than BZ, with the high selectivity index (65) over mammalian cells. LS2/89 was the most potent against bloodstream forms displaying EC50 of 2.67 μM, being over 5-fold more active than BZ. MAIN CONCLUSIONS The positive interaction between multidisciplinary groups, acting as interactive partners in the application of repositioning along with drug combinations, represents a faster and more economical strategy. These studies allow the identification of new therapeutic alternatives with efficacy/safety profiles equal to or superior to those of reference drugs, contributing to drug discovery process against this threatening disease.
DOI
10.1590/0074-02760250374
Autores
Palavras-chave
Edição
Identificação
Página da publicação
Publicado por (Instituto)